Wordt geladen...
The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
BACKGROUND: Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising i...
Bewaard in:
| Gepubliceerd in: | BMC Cancer |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4329195/ https://ncbi.nlm.nih.gov/pubmed/25884855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1066-7 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|